A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers
Information source: St Stephens Aids Trust
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV
Intervention: Raltegravir (Drug); Amlodipine (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: St Stephens Aids Trust Official(s) and/or principal investigator(s): Marta Boffito, Dr, Principal Investigator, Affiliation: St Stephen's AIDS Trust
Summary
The purpose of the study is to look at the levels of an HIV medication (raltegravir) in the
blood, and how it is affected if raltegravir is taken at the same time as another medicine
for high blood pressure (amlodipine). Many patients with HIV will also have high blood
pressure, so it is important to know which drugs for each of these conditions can be taken
together without affecting how well they work individually.
Over a 3 week period, participants took amlodipine for 2 weeks, and raltegravir for 2 weeks,
with the middle week being on both drugs. The investigators will look at and compare the
levels of these two drugs in the blood after subjects have taken them separately and both
together.
This study is randomised into two groups with both study medications received by all
participants in a three-period crossover pattern; randomisation determined which medication
was taken first. Once randomised allocation was performed, medications were administered in
an open-label fashion.
Clinical Details
Official title: A Two Way Cross Over Pharmacokinetic (PK) Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum Observed Concentration (Cmax) of Raltegravir and Amlodipine Without and With Co-administration of the Other Studied Drug.Raltegravir C12h Amlodipine C24h Raltegravir AUC(0-12h ) Amlodipine AUC(0-24h)
Detailed description:
HIV-negative male and female volunteers will be enrolled, after written confirmation of
informed consent, in a phase I, open-label, cross-over, PK study (approved by Westminster
Research Ethics Committee and UK Regulatory Authorities; Eudra number 2012-005400-18).
Subjects are randomized to receive either raltegravir 400mg twice-daily (seven days),
followed by raltegravir 400mg twice-daily plus amlodipine 5mg once-daily (seven days),
followed by amlodipine 5mg once-daily alone (seven days), or the same treatments in the
opposite order, in the fasted state (at least eight hours) with 240mL of water.
Intensive PK sampling and safety laboratory analysis are performed at the end of each phase
(Days 7, 14 and 21). Raltegravir and amlodipine plasma concentrations will be analysed by a
validated liquid chromatography-mass spectrometry (LC-MS/MS) method.
PK parameters are determined by non-compartmental methods [WinNonlin Phoenix (version 6. 1;
Pharsight Corp, Mountain View, CA, USA]. These are the concentrations measured 12 and 24
hours post-dose (C12h, C24h) for raltegravir and amlodipine, respectively; the maximum
concentration (Cmax); and the area under the curve over 12 and 24 hours (AUC12h, AUC24h) for
raltegravir and amlodipine, respectively.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria within 28 days prior to the
baseline visit:
- The ability to understand and sign a written informed consent form, prior to
participation in any screening procedures and must be willing to comply with all
study requirements
- Male or non-pregnant, non-lactating females
- Between 18 to 65 years, inclusive
- Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.
- Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for a period of at least 12
weeks after the study
- Willing to consent to their personal details being entered onto The Over-volunteering
Prevention Scheme (TOPS) database
- Willing to provide photographic identification at each visit.
- Registered with a GP in the UK
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria are not to be enrolled in this
study.
- Any significant acute or chronic medical illness including hypertension (BP
persistently >140/90 mmHg) or hypotension (BP persistently <90/60 mmHg)
- Evidence of organ dysfunction or any clinically significant deviation from normal in
physical examination, vital signs, ECG or clinical laboratory determinations
- Positive blood screen for hepatitis B surface antigen and/or C antibodies
- Positive blood screen for HIV-1 and/or 2 antibodies
- Current or recent (within 3 months) gastrointestinal disease
- Clinically relevant alcohol or drug use (positive urine drug screen) or history of
alcohol or drug use considered by the Investigator to be sufficient to hinder
compliance with treatment, follow-up procedures or evaluation of adverse events.
Smoking is permitted, but tobacco intake should remain consistent throughout the
study
- Exposure to any investigational drug or placebo within 3 months of first dose of
study drug
- Use of any other drugs (unless approved by the Investigator), including
over-the-counter medications and herbal preparations, within two weeks prior to first
dose of study drug, unless approved/prescribed by the Principal Investigator as known
not to interact with study drugs.
- Females of childbearing potential without the use of effective non-hormonal birth
control methods, or not willing to continue practising these birth control methods
for at least 12 weeks after the end of the treatment period
- Previous allergy to any of the constituents of the pharmaceuticals administered in
this trial
- Lactose intolerance
Locations and Contacts
St Stephen's AIDS Trust, London SW10 9TH, United Kingdom
Additional Information
Starting date: April 2013
Last updated: September 23, 2014
|